Advantages and Disadvantages of Hyperbaric Oxygen Treatment in Mice with Obesity Hyperlipidemia and Steatohepatitis

Tsuneyama, Koichi; Chen, Yen‐Chen; Fujimoto, Makoto; Sasaki, Yoshiyuki; Suzuki, Wataru; Shimada, Tsutomu; Iizuka, Seiichi; Nagata, Mitsuru; Aburada, Masaki; Chen, Shaoyuan

doi:10.1100/2011/380236

Cited by 20 publications

(17 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Differing from other gene‐alteration or diet‐induced models that rapidly show severe disturbance of lipid metabolism, ICR–MSG mice gradually developed mild degrees of symptoms with age. Thus, ICR–MSG mice are useful for examining the effects of long‐term mild treatments against various symptoms, such as Kampo medicines and/or functional foods, as well as Western medicines …”

Section: Ms–nash‐hcc Model Micementioning

confidence: 99%

Animal models for analyzing metabolic syndrome‐associated liver diseases

Tsuneyama

Nishitsuji

Matsumoto

et al. 2017

Pathology International

Self Cite

View full text Add to dashboard Cite

Metabolic syndrome (MS) is a worldwide healthcare issue and a dominant risk factor for the development of incurable diseases affecting the entire body. The hepatic manifestations of MS include nonalcoholic fatty liver disease (NAFLD) and its progressive variant, nonalcoholic steatohepatitis (NASH). NASH is known to progress to liver cirrhosis and hepatocellular carcinoma (HCC). Excellent animal models for determining the mechanism of pathogenesis and establishing therapeutic treatment of NASH/HCC are strongly required worldwide. We recently reported that two previously established mouse models of obesity and diabetes mellitus, namely, Tsumura-Suzuki Obese Diabetes (TSOD) mice and MSG mice, developed MS-associated NASH and that their clinical course and pathological characteristics closely mimicked those of human MS-NASH patients. Interestingly, most of the mice developed HCC with advancing age, and the pathological and functional characteristics of this condition were identical to those of human HCC. We further established a novel mouse model of HCC based on type 1 diabetes (DIAR-nSTZ mice) and reported its histopathological features. By comparing various aspects of these mouse models, specific and useful characteristics in a suitable model of MS-associated liver diseases, including hepato-carcinogenesis, can be highlighted.

show abstract

Section: Ms–nash‐hcc Model Micementioning

confidence: 99%

Animal models for analyzing metabolic syndrome‐associated liver diseases

Tsuneyama

Nishitsuji

Matsumoto

et al. 2017

Pathology International

Self Cite

View full text Add to dashboard Cite

show abstract

“…In this sense, hyperoxia exposure has been evaluated as a treatment for obesity and its related disorders [ 5 , 6 ]. Although hyperoxia has shown beneficial effects for obesity management, it may result in nitric oxide (NO) depletion and induction of oxidative stress [ 7 – 9 ]. Interestingly, nitrate, a new proposed therapeutic agent for type 2 diabetes [ 10 ], restores NO depletion and has antioxidant properties [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Hypoxia in Obesity and Diabetes: Potential Therapeutic Effects of Hyperoxia and Nitrate

Norouzirad

González‐Muniesa

Ghasemi

2017

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

The prevalence of obesity and diabetes is increasing worldwide. Obesity and diabetes are associated with oxidative stress, inflammation, endothelial dysfunction, insulin resistance, and glucose intolerance. Obesity, a chronic hypoxic state that is associated with decreased nitric oxide (NO) bioavailability, is one of the main causes of type 2 diabetes. The hypoxia-inducible factor-1α (HIF-1α) is involved in the regulation of several genes of the metabolic pathways including proinflammatory adipokines, endothelial NO synthase (eNOS), and insulin signaling components. It seems that adipose tissue hypoxia and NO-dependent vascular and cellular dysfunctions are responsible for other consequences linked to obesity-related disorders. Although hyperoxia could reverse hypoxic-related disorders, it increases the production of reactive oxygen species (ROS) and decreases the production of NO. Nitrate can restore NO depletion and has antioxidant properties, and recent data support the beneficial effects of nitrate therapy in obesity and diabetes. Although it seems reasonable to combine hyperoxia and nitrate treatments for managing obesity/diabetes, the combined effects have not been investigated yet. This review discusses some aspects of tissue oxygenation and the potential effects of hyperoxia and nitrate interventions on obesity/diabetes management. It can be proposed that concomitant use of hyperoxia and nitrate is justified for managing obesity and diabetes.

show abstract

“…MDA content of the plasma was detected based on the thiobarbituric acid reactive substances (TBARS) assay. The MDA-TBA product formed by the reaction of MDA and thiobarbituric acid (TBA) under high temperature (90-100 • C) and acidic conditions was measured at 540 nm [8].…”

Section: Methodsmentioning

confidence: 99%

“…The effects of hyperoxia on cardiovascular parameters and cytokine production are contradicting. Elevation of reactive species formation during HBOT is proven in animal models and human studies [6][7][8] but it has not been established yet whether this elevation is preserved days or even weeks after the cessation of HBOT. The concern is that elevated reactive radical formation may lead to the worsening of chronic inflammation and cardiovascular status.…”

Section: Introductionmentioning

confidence: 99%

Hyperbaric Oxygen Therapy Dampens Inflammatory Cytokine Production and Does Not Worsen the Cardiac Function and Oxidative State of Diabetic Rats

et al. 2019

View full text Add to dashboard Cite

Hyperbaric oxygen therapy (HBOT) is frequently used after soft tissue injuries and in diabetic patients with ulcerated wounds; however, its ability to increase oxidative stress casts doubts. Diabetes (DM) in male Wistar rats (N = 20) weighing 300 g were induced by a single dose of streptozotocin. Ten diabetics (DMHBOT) and 10 controls (CHBOT) underwent a one-hour long hyperbaric oxygen treatment protocol (2.5 bar) 12 times after the 3rd week of diabetes. Ten animals remained untreated. Eight weeks after diabetes induction, we measured the 24-hour blood glucose profile and cardiovascular function (sonocardiography and the relaxation ability of aortae). Malonyl-dialdehyde (MDA) and cytokine levels were measured in blood plasma. Poly(ADP-ribose) polymerase (PARP) activity was estimated in cardiac and aortic tissue. HBOT did not alter most of the cardiovascular parameters. PARylation in cardiac and aortic tissues, plasma MDA levels were elevated in diabetic rats. HBOT prevented the increase of MDA in diabetic animals. In addition, levels of the pro-inflammatory cytokine-induced neutrophil chemoattractant-1 (CINC-1) the levels of anti-inflammatory tissue inhibitor of metalloproteases-1 were not altered in diabetes or in hyperoxia. Our results suggest that HBOT does not increase long-term oxidative stress, and, similar to training, the TBARS products, nitrotyrosine formation and poly(ADP-ribosyl)ation may be eased as a result of hyperoxia.

show abstract

Advantages and Disadvantages of Hyperbaric Oxygen Treatment in Mice with Obesity Hyperlipidemia and Steatohepatitis

Cited by 20 publications

References 30 publications

Animal models for analyzing metabolic syndrome‐associated liver diseases

Animal models for analyzing metabolic syndrome‐associated liver diseases

Hypoxia in Obesity and Diabetes: Potential Therapeutic Effects of Hyperoxia and Nitrate

Hyperbaric Oxygen Therapy Dampens Inflammatory Cytokine Production and Does Not Worsen the Cardiac Function and Oxidative State of Diabetic Rats

Contact Info

Product

Resources

About